Genmab A/ S stock (DK0010272202): antibody specialist updates outlook after first?quarter results

Genmab A/S has reported new first?quarter 2025 figures and adjusted its full?year outlook, keeping the Danish antibody specialist in focus for US healthcare investors watching the oncology pipeline and partnered royalties.

Genmab A/S has come back into focus after publishing its first?quarter 2025 results and updating its full?year guidance, highlighting both royalty growth from marketed antibodies and higher spending on its clinical pipeline, according to a company release dated 05/08/2025 and coverage by Reuters as of 05/08/2025.

As of: 20.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Genmab
• Sector/industry: Biotechnology, oncology therapeutics
• Headquarters/country: Copenhagen, Denmark
• Core markets: North America, Europe, Japan
• Key revenue drivers: Royalties and milestones from oncology antibodies, proprietary product sales
• Home exchange/listing venue: Nasdaq Copenhagen (GMAB), Nasdaq US (GMAB ADS)
• Trading currency: Danish krone in Copenhagen, US dollar for ADS

Genmab A/S: core business model

Genmab focuses on the discovery and development of antibody?based medicines, particularly in oncology and hematology. The company’s model combines wholly owned drug programs with partnerships in which large pharmaceutical companies commercialize products and pay Genmab royalties and milestones, as described in its annual report published 02/21/2025 for the 2024 financial year, according to Genmab investor relations as of 02/21/2025.

A central element is Genmab’s antibody technology platforms, which are used to create monoclonal and bispecific antibodies that can recognize and attack specific targets on cancer cells. Several of these technologies are licensed to partners, while others are retained for Genmab’s own pipeline. This mixed approach is designed to provide relatively stable royalty income while also leaving upside potential from successfully launched proprietary products.

The group’s best?known marketed products include the blood cancer therapy daratumumab, marketed by Johnson & Johnson under the brand name Darzalex, and other antibodies such as amivantamab and teprotumumab, where Genmab receives royalties. These collaborations reduce the commercial risk compared with fully integrated biopharma models, but they also mean Genmab depends on partners’ pricing, marketing and clinical strategy decisions.

Main revenue and product drivers for Genmab A/S

In the first quarter of 2025, Genmab reported revenue growth driven mainly by higher royalties from its partnered oncology medicines, alongside contributions from collaboration milestones, according to the company’s Q1 2025 report dated 05/08/2025 on its investor site and coverage by Reuters as of 05/08/2025.

Daratumumab remains the most important single driver, as the drug has achieved broad uptake in multiple myeloma across treatment lines. Genmab collects tiered royalties on worldwide sales booked by Johnson & Johnson, and these payments accounted for a significant share of royalty revenue in 2024 and the first quarter of 2025, as stated in the 2024 annual report released 02/21/2025 for that fiscal year, according to Genmab investor relations on that date.

Further contributions come from amivantamab, a therapy for certain forms of non?small cell lung cancer, and teprotumumab, used in thyroid eye disease. Although these products are at earlier stages of their commercial life cycles than daratumumab, royalty lines linked to them have been growing and are expected by management to become increasingly relevant over the medium term, based on statements in the Q1 2025 earnings presentation dated 05/08/2025.

Beyond royalties, Genmab receives milestone payments when development or regulatory events are reached in partnered programs. These inflows can be lumpy, depending on the timing of trial readouts or approvals. In parallel, Genmab is starting to record more revenue from its own marketed medicines, although these products still represent a smaller portion of the overall top line compared with the established royalty streams.

Industry trends and competitive position

Genmab operates in a highly competitive oncology biotechnology landscape, where large pharmaceutical companies and specialized biotechs compete to develop targeted biologics and cell?based therapies. Antibody technologies remain a core treatment modality, but they now coexist with CAR?T cell therapies, antibody?drug conjugates and small?molecule targeted drugs, creating a complex competitive field, as discussed in sector overviews published in early 2025 by major healthcare research providers.

The company’s long?standing expertise in antibody engineering and its track record of bringing partnered products to market help differentiate it among mid?cap biotech peers. Successful collaborations with global players such as Johnson & Johnson have supported Genmab’s reputation as a reliable antibody developer. At the same time, rival platforms for bispecific and next?generation antibodies present ongoing competitive pressure, and the speed of innovation in oncology means that Genmab must continue investing heavily in research and development to maintain its position.

Pricing and reimbursement dynamics also influence Genmab’s prospects indirectly. Many oncology antibodies face scrutiny from healthcare systems and payers regarding cost?effectiveness. Decisions in major markets like the United States or Europe can affect the sales trajectory of products on which Genmab earns royalties, even if the company itself does not set the list price. This adds a policy and market access dimension to Genmab’s risk profile.

Why Genmab A/S matters for US investors

For US investors, Genmab offers exposure to the global oncology therapeutics market through American Depositary Shares listed on Nasdaq under the ticker GMAB. This provides dollar?denominated access to a European biotech with meaningful royalty links to medicines that are widely used in US cancer centers, notably the multiple myeloma therapy daratumumab, according to Genmab’s 2024 annual report dated 02/21/2025.

Because a large portion of Genmab’s royalty revenue is tied to US sales booked by partners, the company’s performance is partly linked to the health of the American healthcare market and reimbursement environment. Changes in US oncology treatment guidelines, competition from generics or biosimilars, or shifts in insurer policies can influence the volume growth of medicines that contribute to Genmab’s top line, even though the company does not sell these products directly in the United States.

Genmab also maintains a growing US research presence, including clinical development activities and collaborations with American academic centers. This footprint can help the company access leading oncology expertise and patient populations, but it also exposes Genmab to US regulatory expectations and clinical trial standards. For US?based shareholders, this combination can make Genmab a way to participate in antibody innovation while spreading risk across different geographic markets.

What type of investor might consider Genmab A/S – and who should be cautious?

Genmab’s business model, which blends recurring royalty income from established oncology products with higher?risk internal R&D projects, tends to appeal to investors interested in biotechnology but looking for some diversification away from single?asset clinical risk. The revenue base from marketed antibodies offers a level of visibility not always present in earlier stage biotechs that rely purely on future trial success, according to management commentary in the 2024 annual report published 02/21/2025.

However, the company still faces typical biotech uncertainties. Clinical trial outcomes for pipeline candidates are not guaranteed, and setbacks can impact sentiment and future growth potential. Moreover, dependency on a limited number of key partnered products means that any slowdown in sales or emerging competition for those medicines can affect royalty trends. Investors with low tolerance for earnings volatility, regulatory risk and scientific uncertainty may therefore approach the stock with caution.

Currency fluctuation adds another layer of complexity. While the Nasdaq?listed ADS trade in US dollars, Genmab reports in Danish krone, and part of its cost base is in European currencies. Movements in exchange rates can influence reported figures and valuations from the perspective of US?based shareholders, especially over longer investment horizons.

Conclusion

Genmab A/S remains a notable European antibody specialist with a hybrid model that combines established royalty streams and an expanding proprietary pipeline. Recent first?quarter 2025 results and updated guidance underline how growth in partnered oncology products continues to support the top line while management allocates more resources to clinical development. For US investors accessing the stock via Nasdaq, Genmab provides indirect exposure to widely used cancer therapies and to innovation in next?generation antibodies. At the same time, reliance on a handful of key royalty?generating drugs, intense competition in oncology and the inherent uncertainties of biotech R&D represent important risk factors that market participants routinely monitor when assessing the stock’s potential.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.